Timber Pharmaceuticals Announces Investor Conference Call
May 19 2020 - 4:41PM
via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the
“Company”) (NYSE American: TMBR), a biopharmaceutical company
focused on the development and commercialization of treatments for
orphan dermatologic diseases, today announced that it will hold an
introductory conference call for its shareholders. This will be the
first investor conference call since the completion of the
Company's recent merger with BioPharmX Corporation (“BioPharmX”)
(NYSE American: BPMX) on May 18, 2020.
The call will be hosted by John Koconis, Chief
Executive Officer of Timber, who will present a corporate overview
of the Company, including its development pipeline and anticipated
milestones.
Conference Call Information
When: Tuesday, May 26, 2020 at 11:00am EDT
Dial in: (877) 270-2148, and ask to be joined into the Timber
Pharmaceuticals, Inc. call
There will also be a live webcast of the conference call which
can be accessed at:
https://services.choruscall.com/links/timberpharma200504.html
For those unable to participate in the
conference call, a replay will be archived and available on
Timber’s website under the Investor Relations tab at
www.timberpharma.com.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases.
The company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. Timber is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and
localized scleroderma. For more information, visit
www.timberpharma.com.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
For further information:
Timber Pharmaceuticals, Inc. John Koconis Chief Executive
Officerjkoconis@timberpharma.com
PCG Advisory Inc. Stephanie PrinceManaging
Director646-762-4518sprince@pcgadvisory.com
BioPharmX (AMEX:BPMX)
Historical Stock Chart
From Apr 2024 to May 2024
BioPharmX (AMEX:BPMX)
Historical Stock Chart
From May 2023 to May 2024